Affiliations: Faculté de Médecine, CNRS – Groupe d'Ingénierie Cellulaire et Tissulaire, Nancy Université – UHP, LEMTA UMR 7563, 54500 Vandoeuvre-les-Nancy, France | Unité de Thérapie cellulaire et tissulaire, CHU Nancy, Nancy, France
Abstract: Osteoarthritis (OA) is a progressive joint disease which represents a combination of several disorders leading to cartilage degradation. The main characteristic of OA is an imbalance between chondrocyte anabolic and catabolic activities. Cytokines produced by the synovium and chondrocytes, especially interleukin 1β (IL-1β) and tumor necrosis factor alpha (TNF-α), play a significant role in the degradation of cartilage. They stimulate the production of nitric oxide (NO), which is involved in cartilage catabolism and also may induce the apoptosis of chondrocytes. The IL-1β produced in activated chondrocytes or synovium may modulate disease progression in OA and should therefore be considered a potential target for therapeutic interventions. Drug and non-drug treatments are used to relieve pain and/or swelling in OA. Diacerein is a slow-acting drug that may slow down the breakdown of cartilage and relieve pain and swelling. It is not clear whether diacerein works but it has been proposed that diacerein acts as a symptom-modifying and perhaps disease-structure modifying drug.
